Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects

[1]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[2]  G. Tedeschi,et al.  Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod , 2022, Multiple Sclerosis and Related Disorders.

[3]  V. De Rosa,et al.  Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects , 2021, Multiple Sclerosis and Related Disorders.

[4]  C. Agrati,et al.  Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies , 2021, Neurology.

[5]  A. Achiron,et al.  Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study , 2021, Journal of Neuroimmunology.

[6]  A. Achiron,et al.  Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose? , 2021, European Journal of Internal Medicine.

[7]  M. Ulivelli,et al.  Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.

[8]  A. Borobia,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[9]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[10]  D. Centonze,et al.  Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus , 2021, Journal of Neurology.

[11]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[12]  M. Dimopoulos,et al.  Organ-specific manifestations of COVID-19 infection , 2020, Clinical and Experimental Medicine.

[13]  M. Trojano,et al.  Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide , 2020, Journal of the Neurological Sciences.

[14]  D. Lauffenburger,et al.  Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.

[15]  V. Meca-Lallana,et al.  Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? , 2020, Multiple Sclerosis and Related Disorders.

[16]  M. Filippi,et al.  COVID-19 in teriflunomide-treated patients with multiple sclerosis , 2020, Journal of Neurology.